

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199726347 B2
(10) Patent No. 724937

(54) Title
Injection needle

(51)⁶ International Patent Classification(s)
A61M 005/32

(21) Application No: **199726347** (22) Application Date: **1997.04.24**

(87) WIPO No: **W097/39787**

(30) Priority Data

(31) Number	(32) Date	(33) Country
491/96	1996.04.24	DK

(43) Publication Date : **1997.11.12**

(43) Publication Journal Date : **1998.01.22**

(44) Accepted Journal Date : **2000.10.05**

(71) Applicant(s)
Novo Nordisk A/S

(72) Inventor(s)
Kim Steengaard; Steffen Lav

(74) Agent/Attorney
SPRUSON and FERGUSON,GPO Box 3898,SYDNEY NSW 2001

(56) Related Art
WO 93/00948
WO 90/07348
EP 279583

OPI DATE 12/11/97 APPLN. ID 26347/97
AOJP DATE 22/01/98 PCT NUMBER PCT/DK97/00188



INTE


AU9726347

(51) International Patent Classification ⁶ : A61M 5/32	A1	(11) International Publication Number: WO 97/39787
(21) International Application Number: PCT/DK97/00188		(43) International Publication Date: 30 October 1997 (30.10.97)
(22) International Filing Date: 24 April 1997 (24.04.97)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SI), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(30) Priority Data: 0491/96 24 April 1996 (24.04.96) DK		
(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).		
(72) Inventors; and (75) Inventors/Applicants (for US only): STEENGAARD, Kim [DK/DK]; Carinaparken 49, DK-3460 Birkerød (DK), LAV, Steffen [DK/DK]; Lavendelgangen 50, Birkevang, DK-2700 Brønshøj (DK).		
(74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsværd (DK).		Published With international search report.

(54) Title: INJECTION NEEDLE

(57) Abstract

A needle mounted in a needle hub fitting onto an injection device from which preset doses of a medicine from a cartridge accommodated in the device is administered through the needle comprises a back needle penetrating a closure membrane of the cartridge and a free injection part shorter than 9 mm, the outer diameter of the needle and the diameter of its bore complying with one of the conditions: a) the outer diameter is smaller than 0,320 mm and the diameter of the bore is larger than 0,165 mm, or b) the outer diameter is smaller than 0,298 mm and the diameter of the bore is larger than 0,133 mm.



Injection needle

The invention relates to injection needles especially needles mounted in a needle hub fitting onto an injection device of the kind from which preset doses of a medicine from a cartridge accommodated in the device may be administered through the needle mounted on the device and exposing a back needle penetrating a closure membrane of the cartridge and a free injection part.

10

Such an injection device, by which doses may be set individually and on which a needle may be mounted and changed after having been used for injection of a medicine from a cartridge in the device, is a common tool for people who have to inject themselves one or more times a day as it is the case by people who are treated with growth hormone or by diabetics who have to inject themselves frequently to keep their blood sugar on an acceptable level.

20

To reduce the malaise by frequent pricking of the skin the trend has lead towards use of still thinner needles as it have shown to cause less pain to be pricked with a fine needle than with a coarse one. With finer needles other problems occur one of them being that e.g. some kinds of insulin has coarse crystals which tends to clog at the inlet to the needle and in this way be sieved from the liquid in which the crystals are suspended. This way the concentration of the insulin injected may differ from what the user think it is which may cause injection of a wrong dose.

30

These problems has according to WO 93/00948 been overcome by using needles mounted in special needle hubs which fit only on devices about which it is known that they will only contain insulin which may flow freely through a thin needle defined as a G30 needle. This is obtained by making devices for which it is guaranteed that they will only contain insulin having a grain size less than 15 μ m and provide the devices

35

with needle receiving pieces onto which the hubs with the fine needles fits. It may be noticed that thicker needles of course may be provided with a corresponding hub as the insulin in the device of course without problems may pass a thicker needle having a larger bore.

Although the G30 needle cause less pain and allow even crystalline insulin to pass provided the crystals have no dimensions larger than 15 μm , the use of these needles are not without problems even by injection of solutions. One of the problems is that a relatively high pressure has to be established in the cartridge from which the medicine shall be pressed out which again means that a excessive force have to be exerted on a manually operated injection button. This may make it difficult to users with weak fingers to perform the injection sufficiently rapidly. With the high pressure in the cartridge, which is mainly of the kind wherein a piston closes one end of an cylinder ampoule whereas the other is closed by a rubber membrane which may be penetrated by a back needle of a double pointed needle to provide communication from the content of the ampoule through the hollow needle to the injection point of this needle, elasticity of the cartridge parts, especially the rubber membrane and the piston, may cause dripping from the needle when this needle is drawn out from the tissue into which it has been inserted during the injection. This means that not the whole set dose is actually injected.

It is the object of the invention to provide a thin needle by which the advantages of the G30 needle is enhanced and/or the drawbacks of this needle are overcome.

This may be obtained by an injection needle of the kind described in the opening of this specification which needle is according to the invention characterised in that the length of the injection part is shorter than 9 mm and that

the outer diameter and bore of the needle complies with one of the conditions:

- 5 a) the outer diameter is smaller than 0,320 mm and
 the diameter of the bore is larger than 0,165 mm,
 or
 b) the outer diameter is smaller than 0,298 mm and
 the diameter of the bore is larger than 0,133 mm.

10 As the standard ISO 9626 describes tolerances for injection
 needles defining that the length of a needle may be one
 millimetre longer or two millimetre shorter than the nominal
 length of the needle, and that for an ordinary G30 the outer
 diameter of the needle must be found within the range between
15 0,320 mm and 0,298 mm, and the diameter of the bore must be
 found within the range between 0,133 mm and 0,165 mm, the
 characterising clause may alternatively be worded as follows:

- that the length of the injection part is nominally 8 mm or
 less, and
 that one of the following two conditions is complied with:
20 a) the outer diameter corresponds to the outer diameter of a
 G30 needle and the bore diameter is larger than the bore
 diameter of an ordinary G30 needle,
 or
 b) the outer diameter is smaller than the outer diameter of a
25 G30 needle and the diameter of the bore is larger than the
 minimum diameter of the bore in an ordinary G30 needle.

30 From WO 93/00948 it is known to use G30 needles for injection
 of insulin from a pen accommodating a cartridge with an insu-
 lin having a maximal crystal size of 15 μm . This will guaran-
 tee that the insulin stored in such injection devices will be
 able to run freely through needles having a bore with diam-
 eter larger than 0,133 mm which is the smallest bore occur-
 ring in a normal G30 needle. Other kinds of medicine not con-
35 taining crystals at all will of course also be able to pass
 such a normal G30 needle.

The use of the smaller wall thickness by needles having outer diameters smaller than 0,320 mm will allow a larger bore in a
5 G30 needle with a resulting better flow through the needle. Alternatively, if a bore diameter of 0,133 mm is accepted the use of thin walls may allow a needle which is still thinner than a G30 needle but which nevertheless guarantees free flow of even a crystalline insulin in the device.

10

Thin walled G30 needles are known , but as it has been the view that thin needles with thin walls should be handled by professionals due to the risk of breaking the needle, thin walled needles have not previously been manufactured for use
15 with injection devices designed for self administration of medicine, e.g insulin. However, as described in WO 93/00948 needles as thin as a normal G30 has shown to be safe for use by self injection and as the bending strength of the needle tube is only reduced 6% when the wall thickness is reduced
20 50% a short thin walled needle will be safe too even in the hand of non professionals.

According to the invention the injection part of the needle is shorter than 9 mm and may appropriately be 4 - 8 mm. With
25 a shorter needle the risk for breaking will be reduced, and further, short needles are to be preferred for subcutaneous injections as the use of short needles reduces the risk of inserting the needle deeper than subcutis. As further the needle is used with an injection device of the kind from
30 which preset doses of a medicine are administrated from a cartridge, the needle part which has to penetrate the closure membrane is the short back needle which may be passed through the membrane without any risk for unallowable bending.

35 In the following the invention is explained in more details with reference to the drawing in which

Figure 1 shows schematically a sectional view of a needle hub with a needle according to the invention, and

Figure 2 shows a sectional view of a section of the needle tube.

In figure 1 a needle is mounted in a needle hub comprising a circular disc shaped element 1 which has along its periphery a circumferential depending sleeve which is on its inner wall provided with a thread 4 by which the needle hub may be screwed onto a needle receiving part of a syringe which needle receiving part is provided with an outer thread. At its centre the element 1 is provided with a protrusion 2 projecting from the disc in the opposite direction of the sleeve. Centrally through the protrusion 2 and the disc element 1 a double pointed needle is mounted so that one pointed end part 5 forming an injection part for piercing the skin of a user protrudes from the protrusion 2 and a so-called back needle 6 protrudes from the opposite side of the circular disc so that it is concentrically surrounded by the sleeve 3. The back needle 6 is shorter than the sleeve 3 so that this sleeve to some extent protect the pointed end of the back needle. The injection part 5 of the needle has a length L which is smaller than 9 mm which is according to ISO 7864:1993E the maximal length accepted for a needle denounced as an 8 mm needle. By limiting and reducing this length the bending moment exerted on the injection part 5 of the needle during insertion of this part through the skin is reduced. The back needle 6 which has to penetrate a closing membrane of an ampoule when the needle is mounted on a syringe is still shorter. This is advantageous as such a membrane is more difficult to penetrate than is the skin. The limited lengths of the unsupported needle makes a reduction of the wall thickness and the resulting reduction of the bending strength acceptable.

Figure 2 shows schematically a sectional view of a section of a needle tube presenting a wall 8 and a bore 7. The needle is characterised by its outer diameter D and the diameter d of the bore. A reduction of the wall thickness may be used for obtaining a larger bore diameter d in a needle as thin as G30 according to ISO 9626 or for obtaining a needle which has a bore diameter d at least corresponding to the minimum diameter of a G30 needle and an outer diameter D smaller than the minimum diameter of a G30 needle. This may be expressed by the conditions:

$$d \geq 0,165 \text{ mm} \quad \text{and} \quad D \leq 0,320$$

or

15

$$d \geq 0,133 \text{ mm} \quad \text{and} \quad D \leq 0,298 \text{ mm}$$

taken with the following condition which must always be complied with: $d + 2 \times (\text{wall thickness}) = D$.

20

The smallest wall thickness which may be accepted is defined by the demands set on the bending strength of the needle.

The claims defining the invention are as follows:

1. An injection needle mounted in a needle hub fitting onto an injection device of the kind from which preset doses of a medicine from a cartridge accommodated in the device may be administered through the needle being mounted on the device and exposing a back needle penetrating a closure membrane of the cartridge and a free injection part, characterised in that the length of the injection part is shorter than 9mm and that the outer diameter and the diameter of the bore of the needle complies with one of the conditions:
 - a. the outer diameter is smaller than 0.320mm and the diameter of the bore is larger than 0.165mm, or
 - b. the outer diameter is smaller than 0.298mm and the diameter of the bore is larger than 0.133mm.
2. An injection needle according to claim 1, wherein the needle wall thickness is greater than 0.039mm.
3. An injection needle according to claim 1 or claim 2, characterised in that the needle hub is designed to fit onto an injection system for insulin.
4. An injection needle according to claim 1 or claim 2, characterised in that the needle hub is designed to fit onto an injection system for insulin analogues.
5. Injection needle according to claim 3 or claim 4, characterised in that the injection system accommodates only cartridges with insulin types which are solutions or suspensions with a particles having a maximum diameter of 15 μ m.
6. An injection needle according to claim 1 or claim 2, characterised in that the needle hub is designed to fit onto an injection system for growth hormones.
7. An injection needle according to any one of claims 1-6, characterised in that the free injection part of the needle has a length in the interval 4-8mm.
8. An injection needle mounted in a needle hub fitting onto an injection device of the kind from which preset doses of a medicine from a cartridge accommodated in the device may be administered through the needle being mounted on the device and exposing a back needle penetrating a closure membrane of the cartridge and a free injection part, substantially as hereinbefore described with reference to the accompanying drawings.

Dated 12 July, 2000

Novo Nordisk A/S

Patent Attorneys for the Applicant/Nominated Person

SPRUSON & FERGUSON






Fig. 1




Fig. 2